Xianlong Ye

571 total citations
28 papers, 425 citations indexed

About

Xianlong Ye is a scholar working on Molecular Biology, Epidemiology and Genetics. According to data from OpenAlex, Xianlong Ye has authored 28 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 6 papers in Epidemiology and 4 papers in Genetics. Recurrent topics in Xianlong Ye's work include Fibroblast Growth Factor Research (17 papers), Kruppel-like factors research (10 papers) and Liver Disease Diagnosis and Treatment (4 papers). Xianlong Ye is often cited by papers focused on Fibroblast Growth Factor Research (17 papers), Kruppel-like factors research (10 papers) and Liver Disease Diagnosis and Treatment (4 papers). Xianlong Ye collaborates with scholars based in China, United States and United Kingdom. Xianlong Ye's co-authors include Yunzhou Wu, Shenglong Zhu, Deshan Li, Guiping Ren, Jianying Qi, Dan Yu, Qiang Wu, Yunye Liu, Bing Zhou and Tianyuan Zhang and has published in prestigious journals such as International Journal of Molecular Sciences, Science Advances and European Journal of Pharmacology.

In The Last Decade

Xianlong Ye

27 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xianlong Ye China 12 263 93 64 41 41 28 425
Yulin Zhou China 11 236 0.9× 82 0.9× 28 0.4× 33 0.8× 33 0.8× 29 462
Linbing Qu China 12 127 0.5× 92 1.0× 63 1.0× 34 0.8× 32 0.8× 22 325
Marie Garcia France 10 256 1.0× 46 0.5× 70 1.1× 37 0.9× 106 2.6× 11 506
Hyeon‐Gun Jee South Korea 11 276 1.0× 47 0.5× 68 1.1× 35 0.9× 85 2.1× 24 470
Rongbei Liu China 9 223 0.8× 37 0.4× 62 1.0× 42 1.0× 63 1.5× 19 439
Chris Chan Hong Kong 8 233 0.9× 152 1.6× 21 0.3× 27 0.7× 46 1.1× 9 570
Naoko Tachibana Japan 8 229 0.9× 38 0.4× 54 0.8× 20 0.5× 57 1.4× 14 388
Gaby El Alam Switzerland 5 199 0.8× 57 0.6× 71 1.1× 68 1.7× 100 2.4× 7 382
Lisa Mayr Austria 10 196 0.7× 120 1.3× 85 1.3× 79 1.9× 50 1.2× 18 431

Countries citing papers authored by Xianlong Ye

Since Specialization
Citations

This map shows the geographic impact of Xianlong Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianlong Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianlong Ye more than expected).

Fields of papers citing papers by Xianlong Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianlong Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianlong Ye. The network helps show where Xianlong Ye may publish in the future.

Co-authorship network of co-authors of Xianlong Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Xianlong Ye. A scholar is included among the top collaborators of Xianlong Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xianlong Ye. Xianlong Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Han, Gaowa Jin, Xianlong Ye, et al.. (2025). Identification of a Novel NPC1L1 Inhibitor from Danshen and Its Role in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences. 26(6). 2793–2793. 1 indexed citations
2.
Zhang, Tingting, Wei Wang, Xianlong Ye, et al.. (2025). Free fatty acid receptor 4 modulates dietary sugar preference via the gut microbiota. Nature Microbiology. 10(2). 348–361. 9 indexed citations
3.
Ye, Xianlong, et al.. (2024). Deciphering the therapeutic efficacy of FGF19 and FGF21 in NAFLD: A comparative genomic and metabolic analysis. Food Bioscience. 60. 104394–104394. 2 indexed citations
4.
Wang, Wei, Xianlong Ye, Zhe Wang, et al.. (2024). Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome. Science Advances. 10(5). eadj7813–eadj7813. 11 indexed citations
5.
Qi, Jianying, Yuanyuan Wu, Zhimou Guo, et al.. (2024). Fibroblast growth factor 21 alleviates idiopathic pulmonary fibrosis by inhibiting PI3K-AKT-mTOR signaling and stimulating autophagy. International Journal of Biological Macromolecules. 273. 132896–132896. 14 indexed citations
6.
Xu, Simeng, Dongqing Chen, Luping Zhou, et al.. (2024). Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21. Microbial Cell Factories. 23(1). 171–171. 5 indexed citations
7.
Ye, Xianlong, Yingli Chen, Jianying Qi, et al.. (2023). Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology. 952. 175811–175811. 10 indexed citations
8.
9.
Zheng, Yi, Jiaqi Li, Zhimou Guo, et al.. (2021). SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate. International Journal of Biological Macromolecules. 193(Pt B). 1124–1129. 31 indexed citations
10.
Ye, Xianlong, Dan Yu, Yunzhou Wu, et al.. (2019). An efficient large-scale refolding technique for recovering biologically active recombinant human FGF-21 from inclusion bodies. International Journal of Biological Macromolecules. 135. 362–372. 13 indexed citations
11.
Yu, Dan, Xianlong Ye, Qiang Wu, et al.. (2017). FGF21 exerts comparable pharmacological efficacy with Adalimumab in ameliorating collagen-induced rheumatoid arthritis by regulating systematic inflammatory response. Biomedicine & Pharmacotherapy. 89. 751–760. 16 indexed citations
12.
Ye, Xianlong, Jianying Qi, Dan Yu, et al.. (2017). Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. Journal of Diabetes and its Complications. 31(4). 726–734. 24 indexed citations
13.
Wu, Yunzhou, Jinjiao He, Jingshu Geng, et al.. (2017). Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. European Journal of Pharmacology. 802. 85–92. 25 indexed citations
14.
Wu, Yunzhou, Jinjiao He, Ying An, et al.. (2016). Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. Journal of Pharmacological Sciences. 132(1). 24–30. 33 indexed citations
15.
Ye, Xianlong, Jianying Qi, Qiang Wu, et al.. (2016). Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity. European Journal of Pharmacology. 781. 198–208. 6 indexed citations
16.
Ye, Xianlong, Jianying Qi, Dan Yu, et al.. (2016). Pilot-scale production and characterization of PEGylated human FGF-21 analog. Journal of Biotechnology. 228. 8–17. 5 indexed citations
17.
18.
Zhu, Shenglong, Yunzhou Wu, Xianlong Ye, et al.. (2016). FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. Molecular and Cellular Biochemistry. 420(1-2). 107–119. 57 indexed citations
19.
Yu, Yin-Hang, Guiping Ren, Yaonan Liu, et al.. (2014). [Effect of FGF-21 on learning and memory ability and antioxidant capacity in brain tissue of D-galactose-induced aging mice].. PubMed. 49(7). 1000–6. 2 indexed citations
20.
Li, Tianhe, Liming Xu, Guiping Ren, et al.. (2013). A Neutralization scFv Antibody against IL-1β Isolated from a NIPA-based Bacterial Display Library. Current Pharmaceutical Biotechnology. 14(6). 571–581. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yulin Zhou Breakdown of academic impact, for papers by Linbing Qu Breakdown of academic impact, for papers by Marie Garcia Breakdown of academic impact, for papers by Hyeon‐Gun Jee Breakdown of academic impact, for papers by Rongbei Liu Breakdown of academic impact, for papers by Chris Chan Breakdown of academic impact, for papers by Naoko Tachibana Breakdown of academic impact, for papers by Gaby El Alam Breakdown of academic impact, for papers by Lisa Mayr
Rankless by CCL
2026